Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: A case report

References

• Birse TM, Lander J. Prevalence of chronic pain. Can J Public Health. 1998;89:129–31.
   PubMed Web of Science ®Google Scholar
• Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333. doi:10.1016/j.ejpain.2005.06.009.
   PubMed Web of Science ®Google Scholar
• Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. Pain Res Manag. 2011;16:445–50.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016;315(15):1624–45. doi:10.1001/jama.2016.1464.
   PubMed Web of Science ®Google Scholar
• Volkow ND, McLellan AT. Opioid abuse in chronic pain–misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–63. doi:10.1056/NEJMra1507771.
   PubMed Web of Science ®Google Scholar
• Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014;120(5):1262–74. doi:10.1097/ALN.0000000000000170.
   PubMed Web of Science ®Google Scholar
• Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain Med. 2014;15(7):1171–78. doi:10.1111/pme.2014.15.issue-7.
   PubMed Web of Science ®Google Scholar
• British Columbia Centre on Substance Use. A guideline for the clinical management of opioid use disorder. Victoria, British Columbia: British Columbia Ministry of Health; 2017.
   Google Scholar
• Aiyer R, Gulati A, Gungor S, Bhatia A, Mehta N. Treatment of chronic pain with various buprenorphine formulations: a systematic review of clinical studies. Anesth Analg. 2018;127(2):529–38. doi:10.1213/ANE.0000000000003570.
   PubMed Web of Science ®Google Scholar
• Fishman MA, Kim PS. Buprenorphine for chronic pain: a systematic review. Current Pain and Headache Reports. 2018;22(83):1–7. doi:10.1007/s11916-018-0732-2.
   PubMedGoogle Scholar
• Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087–94. doi:10.1111/pme.12520.
   PubMed Web of Science ®Google Scholar
• Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78(12):1211–28. doi:10.1007/s40265-018-0953-z.
   PubMed Web of Science ®Google Scholar
• Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003;23(32):10331–37. doi:10.1523/JNEUROSCI.23-32-10331.2003.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569–80. doi:10.1038/clpt.1994.71.
   PubMed Web of Science ®Google Scholar
• Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2 Suppl):S39–47. doi:10.1016/S0376-8716(03)00058-9.
   PubMedGoogle Scholar
• Daniulaityte R, Carlson R, Brigham G, Cameron D, Sheth A. “Sub is a weird drug:” A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms. Am J Addict. 2015;24(5):403–09. doi:10.1111/ajad.12300.
   PubMed Web of Science ®Google Scholar
• Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, Dürsteler KM, Vogel M. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99–105. doi:10.2147/SAR.S109919.
   PubMed Web of Science ®Google Scholar
• Kornfeld H, Reetz H. Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans. Am J Ther. 2015;22(3):199–205. doi:10.1097/MJT.0b013e31828bfb6e.
   PubMed Web of Science ®Google Scholar
• Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, Wolfram G. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage. 2008;36(2):117–25. doi:10.1016/j.jpainsymman.2007.09.011.
   PubMed Web of Science ®Google Scholar
• Gordon A, Callaghan D, Spink D, Cloutier C, Dzongowski P, O‘Mahony W, Sinclair D, Rashiq S, Buckley N, Cohen G, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther. 2010;32(5):844–60. doi:10.1016/j.clinthera.2010.06.017.
   PubMed Web of Science ®Google Scholar
• Neumann AM, Blondell RD, Jaanimägi U, Giambrone AK, Homish GG, Lozano JR, Kowalik U, Azadfard M. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013;32(1):68–78. doi:10.1080/10550887.2012.759872.
   PubMed Web of Science ®Google Scholar
• White LD, Hodge A, Vlok R, Hurtado G, Eastern K, Melhuish TM. Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomized controlled trials. Br J Anaesth. 2018;120(4):668–78. doi:10.1016/j.bja.2017.11.086.
   PubMed Web of Science ®Google Scholar
• Anderson T, Quaye A, Ward E, Wilens T, Hillard P. To stop or not, that is the question: acute pain management for the patient on chronic buprenorphine. Anesthesiology. 2017;125:1180–86. doi:10.1097/ALN.0000000000001633.
   Google Scholar